RBC Capital Rates Eli Lilly and (LLY) Outperform

RBC Capital keeps its bullish outlook on Eli Lilly with a price target of $1,500, a 19.53% upside from the current price.

By TradeTexts Research Desk · Published Oct 16, 2026, 1:54 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

RBC Capital rated Eli Lilly and Company ($LLY) "Outperform" with a $1,500 price target on October 12, 2026.

Since the rating, $LLY is up 6.3% to date (from the $1,182.62 close on Oct 12, 2026).

LLY Eli Lilly and Company

$1,257.03 +16.91% year to date

Daily close · Oct 16, 2026

Key Points

On October 12, 2026, RBC Capital reiterated its Outperform rating on Eli Lilly with a price target of $1,500.
RBC Capital's $1,500 price target implies 19.53% upside from Eli Lilly and Company's ($LLY) current $1,254.96 share price.
As of October 16, 2026, Eli Lilly shares traded recently around $1,254.96, which is below the analyst's target by about 16.3%.
The company has a market cap of approximately $1.12 trillion and reported a trailing twelve-month revenue of about $79.7 billion.

Get $LLY trade alerts by text

We text you when insiders, Congress or big funds trade $LLY. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Eli Lilly and Company alert may contain errors. Disclosures

RBC Capital reiterated its Outperform rating on Eli Lilly and Company (NYSE: LLY) on October 12, 2026, maintaining a price target of $1,500. The stock is currently trading below this target, with shares recently priced at $1,254.96 as of October 16, 2026.

Other Institutional Activity in Eli Lilly

Lilly Endowment, Inc. trimmed its position by 1,516,238 shares, ending with 90,376,978 shares worth about $113.6 billion. Blackrock Inc. increased its stake by 1,161,629 shares, bringing its total to 67,540,400 shares valued at approximately $84.9 billion. Vanguard Capital Management LLC added 165,427 shares, resulting in 53,528,868 shares valued at around $67.3 billion. Meanwhile, PNC Financial Services Group, Inc. slightly reduced its holdings by 5,133 shares, totaling 51,322,720 shares worth about $64.5 billion. State Street Corporation increased its position by 605,376 shares, ending with 36,215,754 shares valued at approximately $45.5 billion.

Eli Lilly and Company Stock Up 3.8%

Eli Lilly shares are currently trading above their 50-day moving average by about 6.4% and above the 200-day average by about 16.3%. However, the stock is below its 52-week high of $1,292.65 by about 2.9%. The recent trading price also sits about 5.5% below the average analyst target of $1,328.05.

12-month forecast

$LLY price target

Eli Lilly and Company daily closes and this analyst's $1,500 target. Not advice.

Recent Earnings

Eli Lilly reported trailing twelve-month revenue of approximately $79.7 billion, with a year-over-year revenue growth of 47.7%. The company's net margin stands at 33.5%, and it has a return on equity of 102.3%. The next earnings report is scheduled for October 29, 2026.

Insider Buying and Selling at Eli Lilly and Company

Recent insider transactions include Ilya Yuffa, an officer, who sold 2,500 shares at an average price of $1,150.77 on June 10, 2026, valued at about $2.88 million. Anat Hakim, General Counsel, sold 5,000 shares at $1,190.00 on August 7, 2026, totaling $5.95 million. Donald A. Zakrowski, also an officer, sold 2,000 shares at $1,185.01 on August 10, 2026, valued at around $2.37 million. Lastly, Patrik Jonsson, another officer, sold 6,500 shares at $1,175.10 on August 17, 2026, worth approximately $7.64 million.

Analysts Set New Price Targets

On October 12, 2026, RBC Capital reiterated its Outperform rating on Eli Lilly with a price target of $1,500. Earlier, JP Morgan maintained its Overweight rating with a target of $1,500 on September 28, 2026, up from $1,400. Morgan Stanley also maintained its Overweight rating with a target of $1,430 on October 7, 2026, while Cantor Fitzgerald set a target of $1,440 on October 8, 2026.

About Eli Lilly

Eli Lilly and Company is a global pharmaceutical company based in Indianapolis, Indiana. It focuses on discovering, developing, manufacturing, and marketing human pharmaceutical products across various regions, including the United States, Europe, and Asia. The company plays a vital role in the healthcare sector, addressing various medical needs.

Bottom Line

Investors will be watching for Eli Lilly's upcoming earnings report on October 29, 2026, to gauge its performance. RBC Capital's continued bullish outlook reflects confidence in the company's growth potential amid a competitive industry landscape.